Pharmacological effects and the related mechanism of scutellarin on inflammation-related diseases: a review

Inflammation is a biological response of multicellular organisms caused by injuries, pathogens or irritants. An excessive inflammatory response can lead to tissue damage and various chronic diseases. Chronic inflammation is a common feature of many diseases, making the search for drugs to treat inflammation-related diseases urgent. Scutellarin, a natural flavonoid metabolite, is widely used in the treatment of various inflammation-related diseases for its anti-inflammatory, anti-oxidant and anti-cancer activities. Scutellarin can inhibit key inflammatory pathways (PI3K/Akt, MAPK, and NF-κB, etc.) and activate the anti-oxidant related pathways (Nrf2, ARE, ect.), thereby protecting tissues from inflammation and oxidative stress. Modern extraction technologies, such as microwave-assisted, ultrasound assisted, and supercritical fluid extraction, have been utilized to extract scutellarin from Scutellaria and Erigeron genera. These technologies improve efficiency and retain biological activity, making scutellarin suitable for large-scale production. Scutellarin has significant therapeutic effects in treating osteoarthritis, pulmonary fibrosis, kidney injury, and cardiovascular diseases. However, due to its low bioavailability and short half-life, its clinical application is limited. Researchers are exploring innovative formulations (β-cyclodextrin polymers, triglyceride mimetic active ingredients, and liposome precursors, etc.) to improve stability and absorption rates. Despite these challenges, the potential of scutellarin in anti-inflammatory, anti-oxidant, and anti-cancer applications remains enormous. By optimizing formulations, exploring combination therapies, and conducting in-depth mechanistic research, scutellarin can play an important role in treating various inflammatory diseases, providing patients with more and effective treatment options.


Introduction
Inflammation is a biological response of multicellular organism caused by sensitizing stimuli including damaged cells, pathogens or irritants.Moderate inflammatory response plays a crucial role in our long-term health through clearing infections and repairing tissue damage (Goodman et al., 2019;Henein et al., 2022;Soliman and Barreda, 2022).While over-activation of inflammation could lead to tissue damage and various chronic diseases.Chronic inflammation is a well-recognized feature of most diseases, dramatically increasing global morbidity and mortality (Xia et al., 2023).Osteoarthritis (OA) is the most universal inflammatory disease of the joints (about 1 billion people), which brought an economic burden of nearly $140 billion (Wang et al., 2024).It is estimated that the majority of people suffer from OA by the age of 40-50 years and the incidence of OA is increasing due to the aging population and the high incidence rate of obesity (Jiang et al., 2024).Fibrosis, resulting from impaired tissue repair and remodeling, is a common long-term outcome of chronic inflammatory diseases (Massoud et al., 2024).Pulmonary fibrosis is characterized by fibroproliferation and abnormal tissue repair after injury, which could exacerbate the pathological process of pulmonary fibrosis through oxidative stress and inflammation-induced immune responses (Li Z. et al., 2024).In addition, inflammation is an important cause of excessive cardiovascular risk and progressive kidney injury.Chronic kidney disease accelerated dysregulation of the innate and adaptive immune systems, which would make the systemic inflammation and localized vascular inflammatory responses increase continuously, ultimately lead to atherosclerosis and microcirculatory dysfunction (Huck et al., 2024).That's why the research for drugs to treat inflammationrelated diseases is so urgent.
Scutellarin, a natural flavonoid isolated from the root of Scutellaria baicalensis Georgi [Lamiaceae; Scutellaria], has been extensively used in the treatment of various diseases for its valuable biological activities, such as anti-oxidant, antiinflammatory, and anti-cancer activities (Bian et al., 2020;Song et al., 2020).The mechanism by which scutellarin prevented and treated inflammation-related diseases included inhibiting the production of inflammatory mediators or oxidative stress responses.Cytokines and chemokines mediate the recruitment, activation, and proliferation of neutrophils, and promote the extravasation of monocytes and macrophages to the site of inflammation.These pro-inflammatory cytokines (IL-1, IL-6 and TNF-α, etc.) can activate the inflammatory cascades, thereby exacerbating organ and tissue injuries (Duan et al., 2024).Researches have shown that scutellarin can inhibit the production of these cytokines and reduce inflammatory responses (Cao et al., 2019;Aksit et al., 2023).For example, NF-κB is a key transcription factor that coordinates the expression of multiple genes associated with inflammatory responses (Mussbacher et al., 2023).Scutellarin can reduce the secretion of inflammatory mediators and significantly regulate the production of immune effector factors by mediating the NF-κB signaling pathway (Zhang et al., 2022).In addition, oxidative stress is another factor that exacerbates tissue damage caused by inflammatory reactions.The reactive oxygen species (ROS) produced during oxidative stress can activate various inflammatory signaling pathways, thereby promoting inflammation cascades.Scutellarin has been reported to have anti-oxidant properties, which can clear ROS, thereby reducing oxidative stress and reversing the trend towards inflammation (Zhang et al., 2022).
Scutellarin may have significant advantages in the treatment of inflammation-related diseases.Nevertheless, the low bioavailability and short half-life of flavonoids have limited the therapeutic efficacy of scutellarin in inflammation-related diseases.To solve the problem, researchers are committed to exploring new formulations of flavonoids including polymeric nanoparticles, liposomes, solid lipid microparticles, nanogels and nanocrystals (Sharma and Wairkar, 2024).However, whether the new formulations of scutellarin are economical, safe and effective is yet to be investigated, and the direction of specific drug dosage forms and delivery modalities of scutellarin still need to be explored in greater depth.Up to date, there has not been a systematic and complete review of the specific mechanisms of scutellarin against inflammation-related diseases, which has hindered its application and development as a good antiinflammatory agent.This review is to provide valuable information for future applications of scutellarin in preventing and treating inflammation-related diseases.

Main sources and extraction methods of scutellarin
Scutellarin is a flavonoid glycoside mainly present in Scutellaria and Erigerontis genera (Chledzik et al., 2018).Scutellarin is frequently existed in S. baicalensis (Pei et al., 2022), and it was also identified in Scutellaria lateriflora L.
[Lamiaceae; Scutellaria], Scutellaria barbata D.Don [Lamiaceae; Scutellaria], and Oroxylum indicum (L.) Kurz [Bignoniaceae; Oroxylum] as well.The Scutellaria genus is widely distributed in east Asia and north America (Irvin et al., 2019).The roots, stems and leaves of these plants contain large amounts of scutellarin.Breviscapine, the extract of Erigeron brevisacapus (Vaniot) Hand.-Mazz.[Compositae; Erigeron] that is rich in scutellarin, has been reported to be effective for improving blood circulation.Studies revealed that the contents of scutellarin varied significantly depending on the plant species and parts (Georgieva et al., 2020).For example, the roots of S. baicalensis and the whole herb of E. brevisacapus are the main resources for extracting scutellarin (Nurul Islam et al., 2011;Georgieva et al., 2022).The sources of scutellarin and its available extraction methods were shown in Figure 1.
The extraction methods of scutellarin included traditional extraction techniques and modern extraction techniques (Hao et al., 2020).For traditional extraction methods (solvent extraction and hot reflux extraction), various solvents such as ethanol, methanol, or water can be used to extract scutellarin from plant materials (Yang et al., 2019b).Although these methods are easy to operate and have low equipment costs, they have disadvantages such as low efficiency and long-time consumption.With the development of science and technology, modern extraction techniques have greatly improved the extraction efficiency and purity of scutellarin (Xia et al., 2021).Ultrasound assisted extraction (UAE) utilizes the cavitation effect of ultrasound to accelerate the contact between solvents and plant materials, which could improve extraction efficiency, reduce solvent usage, and achieve an extraction rate of 50%-60% for scutellarin (Xiang and Wu, 2017).Microwave assisted extraction (MAE) utilizes microwave energy to rapidly heat solvents and plant materials, rapidly damaging cell walls and releasing scutellarin.The extraction rate of scutellarin is very high (about 70%-80%) (Li et al., 2015).Supercritical fluid extraction (SFE) uses supercritical carbon dioxide as a solvent under high pressure to preserve the biological activity of scutellarin, with an extraction rate of approximately 60%-70% (Yang and Wei, 2018;Yang et al., 2019a).These modern technologies not only have significant advantages in extraction efficiency, but also maintain the biological activity of scutellarin, making them suitable for largescale industrial production and high-value extraction.The advantages and disadvantages of scutellarin extraction methods were summarized in Table 1.  3 Role of scutellarin on inflammatory signaling pathways 3.1 Inhibition of NF-κB pathways

Inhibition of IKK activation and IκBα phosphorylation
Under normal circumstances, nuclear factor-kappa B (NF-κB) was present in the cytoplasm as an inactive state, which was combined with the IκB proteins (Barnabei et al., 2021).When inflammatory response (such as LPS, cytokines, etc.) was initiated (Yang et al., 2021), the IκB kinase (IKK) complex would be activated (Moser et al., 2021), leading to IκBα phosphorylation, which could further promote the release of NF-κB and the degradation of the IκBα (Shen et al., 2019).Scutellarin could inhibit the activated IKK, thereby preventing the degradation and phosphorylation of IκBα (Peng et al., 2020;Park et al., 2022).As a consequence, scutellarin could make NF-κB binding to IκBα in the cytoplasm, and the inactivated NF-κB cannot exert its effects (Lu et al., 2021;Xu et al., 2021).

Prevention of NF-κB nuclear translocation
NF-κB translocation from the cytoplasm to the nucleus is necessary for inflammatory gene transcription.Scutellarin inhibited the nuclear translocation of the p65 subunit by stabilizing IκBα (Giridharan and Srinivasan, 2018).Studies indicated that the nuclear distribution of NF-κB p65 subunit was mainly present in the cytoplasm after scutellarin treatment (Wang et al., 2011;You et al., 2018).Scutellarin prevented nuclear translocation of NF-κB and thus inhibited its activity (Peng et al., 2020).

Reduction of NF-κB target gene expression
After entering into the nucleus, NF-κB activated transcription of a set of inflammatory genes (Alharbi et al., 2021).Scutellarin suppressed the expression of these inflammatory genes to attenuate inflammation.It has been shown that scutellarin significantly reduced LPS-induced mRNA and protein levels of IL-1β, IL-6, TNF-α, COX-2, and iNOS (Peng et al., 2020;Park et al., 2022;Aksit et al., 2023;Zhang et al., 2023;Duan et al., 2024).Scutellarin could alleviate the local and systemic inflammatory Frontiers in Pharmacology frontiersin.orgresponse through decreasing the expression of those proinflammatory mediators in vivo (Figure 2).

Inhibition of MAPK pathways
The major isozymes of the mitogen-activated protein kinase (MAPK) family included p38, JNK and ERK (Guo et al., 2020;Iroegbu et al., 2021;Van Gerrewey and Chung, 2024), the front two are closely related to inflammation.Scutellarin can be used as a therapeutic agent to inhibit inflammation by modulating the MAPK pathways.

Regulation of the JNK pathway
The JNK (c-Jun N-terminal kinase) signaling pathway is involved in cell stress response, apoptosis and inflammation.The JNK pathway is activated when cells are exposed to ultraviolet (UV) light, oxidative stress and cytokines (Liu B. et al., 2020).Upon activation, JNK can make the downstream transcription factor c-Jun phosphorylation, which plays a key role in gene expression associated with cell stress response or apoptosis.It has been demonstrated that dysregulated JNK signaling is closely related to numerous inflammatory diseases as well as cancers (Zhang et al., 2019).Scutellarin influenced the process of inflammation by regulating multiple factors of the JNK pathway.Scutellarin prevented JNK phosphorylation, thereby leading to the decrease in pro-inflammatory gene expression (You et al., 2018;Deng et al., 2024).Moreover, scutellarin also significantly reduced inflammation via inhibiting IL-1β and TNF-α production (You et al., 2018;Sun et al., 2019;Chen H. L. et al., 2020).

Regulation of the p38 pathway
The p38 pathway plays a key role in cellular stress response and inflammation (Yong et al., 2009).It is activated by stress kinases such as MKK3 and MKK6 (Rossa et al., 2006), which phosphorylate and activate downstream effector proteins, thereby affecting the production of inflammatory factors, cell proliferation, differentiation, and apoptosis.Scutellarin regulates the p38 pathway through various specific mechanisms, thereby exerting its anti-inflammatory effects (You et al., 2018).Scutellarin can also reduce the phosphorylation levels of transcription factors ATF2 and CHOP, causing the low expression of inflammatory genes (Wang Z. et al., 2022).Together, these results demonstrated that scutellarin could exert the potent anti-inflammation effects through regulating p38 pathway (Figure 3).

Regulation of PI3K/Akt Pathway
The phosphatidylinositol 3-kinase/protein kinase B (PI3K/ Akt) pathway plays a critical role in cell growth, survival, proliferation, and metabolism (Yong et al., 2009;Deng and Zhou, 2023).Aberrant activation of the PI3K/Akt pathway is strongly associated with cancer and inflammatory diseases (Alzahrani, 2019;Ghafouri-Fard et al., 2021).Scutellarin exerted the anti-inflammatory and anti-cancer effects through regulating the PI3K/Akt pathway (Wang et al., 2019;Hu et al., 2022).Mechanistically, receptor phosphorylation recruits and activates PI3K, which phosphorylates PIP2 to PIP3 (Carnero et al., 2008).The PH structural domain of Akt binds to PIP3, which recruits Akt to the cell membrane, thereby localizing Akt to the cell membrane and activating it.Akt is then phosphorylated and activated by pyruvate dehydrogenase kinase, isozyme 1 (PDK1) and mechanistic target of rapamycin complex 2 (mTORC2) (Xu et al., 2020).The fully activated Akt then enters the cytoplasm or nucleus to phosphorylate its downstream effector proteins.Scutellarin could inhibit PI3K activity, prevent phosphatidylinositol 4,5-bisphosphate 3 (PIP3) production, reduce Akt membrane localization, and directly inhibit Akt phosphorylation (Zhang et al., 2023).In this way, Akt could not be effectively phosphorylated, leading to the inactivated downstream effector proteins (mTOR, Bax, etc.) (Ju et al., 2021;Wang Z. et al., 2022).mTOR could promote the production of proinflammatory cytokines (such as IL-6 and TNF-α) by regulating translation factors 4E-BP1 and S6K.Therefore, inhibiting mTOR activity can reduce the expression of pro-inflammatory cytokines and alleviate the inflammatory response.Many current studies have discovered that scutellarin greatly reduced Akt-mediated proinflammatory cytokines such as TNF-α, IL-1β and IL-6, thereby attenuating the inflammatory response and tissue damage (Figure 4).

Activation of Nrf2/ARE pathway
The nuclear factor E2-associated factor 2/anti-oxidant response element (Nrf2/ARE) pathway is a key regulatory mechanism for cellular anti-oxidant and detoxification responses (Zgorzynska et al., 2021).Normally, Nrf2 is inhibited by kelch-like ECH-associated protein 1 (Keap1) protein and localized in the cytoplasm (Panieri and Saso, 2021;Song et al., 2021).Under oxidative stress or electrophilic conditions, Nrf2 is released from Keap1 and translocated to the nucleus.It has been shown that scutellarin promoted the nuclear translocation and release of Nrf2 by interfering with the interaction between Nrf2 and Keap1 (Li J. et al., 2023;Shahmohammadi et al., 2023).After entering the nucleus, Nrf2 initiates transcription of anti-oxidant genes through binding to ARE.Activated Nrf2 regulates the expression of a range of anti-oxidant, detoxification and anti-inflammation enzymes, such as heme oxygenase-1 (HO-1) (Zhang et al., 2023) and superoxide dismutase (SOD) (Shahmohammadi et al., 2023;Xie et al., 2023).By triggering the Nrf2/ARE pathway, scutellarin increases the expression levels of these anti-oxidant enzymes, which enhances cellular anti-oxidant capacity and protects cells from oxidative stress toxic damage and inflammation (Figure 5).

Specific role of scutellarin in inflammation-related diseases
Due to the obvious anti-inflammation and anti-oxidative effects, scutellarin has been used to treat osteoarthritis, pulmonary fibrosis, kidney injury and cardiovascular diseases (Table 2).

Mechanism of action Trends in action Refs
Frontiers in Pharmacology frontiersin.org08 Zhou et al. 10.3389/fphar.2024.1463140from degradation.Moreover, scutellarin can slow down the progression of osteoarthritis by reducing inflammation-related protein expression in chondrocytes, which may be attributed to its inhibitory effect on the PI3K/AKT/mTOR pathway (Ju et al., 2021).Scutellarin can also enhance the expression of Nrf2 dependent HO-1 by binding to Nrf2, thus reducing inflammation and matrix degradation (Luo et al., 2020).As high cholesterol levels are the high risks of OA, scutellarin can reduce the progression of OA through regulating cholesterol metabolism related proteins (CH25H, CYP7B1, ABCA1, and APOA-1) (Choi et al., 2019), In summary, scutellarin has potential therapeutic value in the treatment of OA by inhibiting the NF-κB, MAPK, PI3K/AKT/ mTOR, and Wnt/β-catenin pathways, as well as regulating the expression of cholesterol metabolism related proteins (Figure 6).

Pulmonary fibrosis
Pulmonary fibrosis is an irreversible lung disease characterized by collagen deposition in the alveolar spaces.Inflammatory response and oxidative stress are closely related to the pathogenesis of pulmonary fibrosis (Liu M. H. et al., 2017).Research has shown that scutellarin can alleviate the inflammatory response of pulmonary fibrosis by inhibiting the production of various inflammatory factors (Peng et al., 2020).Scutellarin has significant anti-pulmonary fibrosis effects by acting on the TGFβ/Smad and NF-κB signaling pathways (Liu et al., 2019) Furthermore, scutellarin can directly inhibit the activation, proliferation, and production of collagen in fibroblasts (Luo et al., 2020), thus slowing down the pathological process of pulmonary fibrosis (Liu et al., 2019;Ma et al., 2020).Scutellarin can also alleviate lung tissue damage caused by oxidative stress via activating the Nrf2/ARE signaling pathway, and increasing the expression of anti-oxidant related enzymes (SOD, CAT, and HO-1, etc.) (Hao et al., 2023).Some studies have shown that scutellarin can reduce the expression levels of fibronectin, MMPs, and TIMP (Peng et al., 2020), thereupon then prevent extracellular matrix (ECM) deposition and maintain lung structure (Zhou et al., 2019).In summary, scutellarin reduces ECM deposition by blocking the production of inflammatory factors, reducing oxidative stress, and inhibiting fibroblast proliferation, thereby playing a therapeutic role in pulmonary fibrosis.These mechanisms reveal the broad prospects of scutellarin in the treatment of pulmonary fibrosis.

Kidney injury
Kidney injury is a common clinical syndrome characterized by decreased renal function resulting from the accumulation of metabolic waste and toxins in the body (Li et al., 2022).Inflammatory response and oxidative stress play key roles in the pathogenesis of kidney injury (Andrianova et al., 2020).Scutellarin inhibits the production of pro-inflammatory cytokines by suppressing the NF-κB signaling pathway, thereby alleviating inflammatory damage to renal tissue (Liu et al., 2022).Scutellarin can also increase the expression of anti-oxidant enzymes (SOD, CAT, HO-1, etc.) by activating the Nrf2/ARE signaling pathway, thereby protecting kidney tissue from oxidative stress damage (Shahmohammadi et al., 2023).In addition, scutellarin protects renal function by inhibiting the PI3K/Akt pathway and reducing Diagram of the mechanism of action of scutellarin in the treatment of osteoarthritis, Created with MedPeer (medpeer.cn).
apoptosis of renal tubular epithelial cells (TECs) (Liu et al., 2022).TGF-β and Smad proteins can activate the production of fibrosis markers (collagen, fibronectin, etc.), while scutellarin can precisely inhibit the expression of TGF-β and Smad, and then reduced renal fibrosis (Wang H. et al., 2022).In summary, the effects of scutellarin on renal injury may be mediated through multiple pathways, such as inhibiting inflammation, oxidative stress, apoptosis of renal tubular epithelial cells, and renal fibrosis.

Cardiovascular diseases
Cardiovascular diseases (CVDs) are the leading cause of death and disability worldwide, closely associated with oxidative stress and inflammatory responses (Zhong et al., 2019).Scutellarin has antiinflammatory and anti-oxidant properties, which can reduce the occurrence of CVDs.Scutellarin can inhibit the MAPK and NF-κB signaling pathways, thus reducing the inflammatory response caused by cardiovascular injury models (Zhang et al., 2022).Scutellarin can also reduce ROS production by activating the Nrf2/ARE signaling pathway, further alleviated oxidative stressinduced cardiovascular damage (Wang and Ma, 2018;Zhang et al., 2023).In addition, scutellarin can reduce the accumulation of lipids and the formation of foam cells (Gao et al., 2024), thereby reducing the generation of atherosclerosis.Remarkably, scutellarin can stabilize atherosclerotic plaque, reduce the risk of plaque rupture, and limit the occurrence of subsequent cardiovascular events (Xu et al., 2021).In summary, scutellarin has preventive and therapeutic effects on cardiovascular diseases by inhibiting the production of inflammatory factors, reducing oxidative stress levels, and stabilizing plaques.

Pharmacokinetic characterization of scutellarin and dosage form modification studies
Although scutellarin exerted strong anti-inflammatory activity in many cellular experiments, in vivo pharmacokinetic studies have indicated that scutellarin have some shortcomings for the treatment effects.The absolute oral bioavailability of scutellarin in Beagle dogs was reported to be 0.40% ± 0.19% (Ge et al., 2003), which was hardly absorbed.Scutellarin is also rapidly metabolized and excreted after intravenous injection, with a short elimination half-life of (52 ± 29) min (Jiang et al., 2003;Wu et al., 2021).Moreover, the chemical structure of scutellarin has phenolic hydroxyl group, it will be easy to produce precipitation in acidic solution.Studies have shown that flocculent precipitation could occur when scutellarin is dissolved in the infusion solution with pH < 3.8 (Xu et al., 2012), which implies that its absorption is reduced in gastrointestinal tract, partly explaining the low bioavailability.
To address the problem, more and more modern technologies have been gradually applied to improve the effectiveness of scutellarin.On the one hand, various special materials are used to improve the dosage form.For example, β-cyclodextrin suspension polymers are used as carriers to enhance the solubility of scutellarin (Liao et al., 2020); the triglyceride mimetic prodrug of scutellarin was designed to promote intestinal lymphatic transport and improve Forms and modes of administration of scutellarin, Created with MedPeer (medpeer.cn).
Frontiers in Pharmacology frontiersin.org10 oral bioavailability (Wang et al., 2021); liposome precursors of scutellarin were also prepared using liposome technology, which improved the stability of scutellarin in vivo and enhanced its bioavailability (Luo et al., 2019).Furthermore, other new dosage forms, such as encapsulation technology, self-microemulsion, and fat emulsion, have also been widely used in the study of scutellarin formulations, which have improved the bioavailability, solubility and safety of scutellarin (Tian et al., 2014).On the other hand, the drug targeting of scutellarin was also explored in various ways.For cerebrovascular diseases, the blood-brain barrier was a major pain point hindering drug action, for which administration via the nasal route has emerged (Liu and Ho, 2017).In situ gels based on nanosuspensions have been developed as intranasal delivery formulations of scutellarin and have been shown to improve its solubility and bioavailability, as well as prolong its retention time in the nasal cavity (Chen Y. et al., 2020).PLGA-PEG-AEAA nanoformulations of scutellarin have been developed to promote tumor delivery (Li L. et al., 2023).Besides, the traditional coating technology was also introduced to increase drug targeting.Scutellarin could be prepared as a colon-localized coated tablet, and the drug would be released on the colonic site at pH > 7.0, which significantly promoted the colon-targeted drug delivery (Li et al., 2013) (Figure 7).

Discussion
As a natural flavonoid, scutellarin possesses significant antiinflammatory properties, and has been identified as a promising candidate drug for the treatment of multiple inflammation-related diseases.According to the existing publications, the antiinflammatory effects of scutellarin could be attributed to acting on several key inflammation signaling pathways such as MAPK, NF-κB, and PI3K/Akt, which reduced the production of proinflammatory mediators and consequently attenuated inflammation (Chen H. L. et al., 2020;Liu F. et al., 2020).Scutellarin can inhibit the activation of NF-κB, thereby reducing the expression of TNF-α and IL-1β (Ju et al., 2021;Aksit et al., 2023;Li J. et al., 2023).In addition, scutellarin can exert anti-oxidant effects by triggering the Nrf2/ARE signaling pathway and increasing the expression of anti-oxidant enzymes, thus reducing cell damage caused by oxidative stress (Xie et al., 2023).These results indicated that scutellarin have potential application value in the prevention and treatment of various inflammation-related diseases, such as osteoarthritis (Wang et al., 2019;Liu F. et al., 2020;Zahan et al., 2020;Yang et al., 2022), pulmonary fibrosis (Hao et al., 2023), ischemia/reperfusion injury (Xie et al., 2023), cisplatin induced acute renal injury (Shahmohammadi et al., 2023), and diabetes induced cardiomyopathy (Xu et al., 2021).
According to the latest research results, the clinical application prospects of scutellarin are very broad.Scutellarin is a naturally extracted metabolite with good safety (Sun et al., 2019;Zhang et al., 2020), making it an ideal molecule for clinical applications.The multi-target ability of scutellarin makes it an anti-inflammatory drug with a wide range of pharmacological effects on complex inflammatory diseases (Peng et al., 2020).Researchers are currently researching new dosage form technologies to overcome the drawbacks caused by the properties of scutellarin, such as increasing the solubility and dissolution rate of scutellarin.These new dosage forms could not only increase the bioavailability, but also improve medication safety.However, there are still some problems in the dosage form studies, such as repetitive experiments, in vivo pharmacokinetics and drug release behavior studies.Hence, it is necessary to carry out in-depth studies on the in vivo pharmacokinetics and biopharmacy of the new dosage form.Moreover, the opening of new routes of drug delivery (transdermal, mucosal, nebulization, etc.) may bring new perspective to the drug development of scutellarin.Precision therapy should also be incorporated in the pre-clinical investigation of scutellarin using genomics and proteomics technologies.
In conclusion, scutellarin, as a typical flavonoid with multiple pharmacological effects and low toxicity, can be applied in antiinflammatory, anti-oxidant and antitumor fields in the future.It is believed that scutellarin will play a prominent role in the treatment of various inflammatory diseases and provide new therapeutic options for patients through optimized formulations, combination therapies and in-depth studies on its mechanism.